• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Preclinical Breakthrough in Age-Reversal Model With Telomir-1

By: Investor Brand Network
June 05, 2025 at 09:45 AM EDT

Telomir Pharmaceuticals (NASDAQ: TELO) announced new preclinical results showing that its lead candidate, Telomir-1, significantly reverses multiple aging markers in a zebrafish model of Werner Syndrome, a rare disorder mimicking accelerated human aging. The orally administered compound extended telomere length by threefold, restored muscle mass and body weight, reduced oxidative stress, and reversed age-related DNA methylation loss. Treated animals also showed a survival benefit compared to controls. CEO Erez Aminov described the findings as a potential milestone in aging science, reinforcing the company’s commitment to advancing Telomir-1 toward human clinical trials.

To view the full press release, visit https://ibn.fm/4xZuO

About Telomir Pharmaceuticals

Telomir Pharmaceuticals is a preclinical stage pharmaceutical company seeking to lead development in longevity science in both humans and animals. The company is focused on the development of Telomir-1, a novel small molecule designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomeres are the protective end caps of a chromosome made up of DNA sequences and proteins. As humans age, telomeres shorten, with metal reactivity accelerating the process, which presents humans and pet animals with an increased chance of contracting a number of degenerative and age-related diseases. Telomir’s goal is to develop, gain regulatory approval for and commercialize Telomir-1, proposed to be dosed orally, with the broader aim of promoting longevity and enhancing overall quality of life. For more information about the company, visit the website www.Telodx.com.

NOTE TO INVESTORS: The latest news and updates relating to TELO are available in the company’s newsroom at https://ibn.fm/TELO

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

More News

View More
Got 1K to Invest? These 3 Stocks Are Still Attractive Buys
Today 16:26 EDT
Via MarketBeat
Topics Artificial Intelligence
Tickers AMD LLY NVDA UBER
Why Micron Stock Could Soar 35% on AI Memory Demand
Today 15:12 EDT
Via MarketBeat
Topics Artificial Intelligence
Tickers AMD LNVGY MU NVDA ORCL
5 Reasons Coca-Cola Stock Will Hit New Highs This Year
Today 14:47 EDT
Via MarketBeat
Tickers KO
GE Aerospace Can Rally Through Year’s End and Into 2026
Today 13:29 EDT
Via MarketBeat
Tickers GE
WesBanco Insiders Signal Confidence With Coordinated Buys
Today 11:04 EDT
Via MarketBeat
Tickers WSBC

Recent Quotes

View More
Symbol Price Change (%)
AMZN  222.03
+5.55 (2.56%)
AAPL  262.77
+0.53 (0.20%)
AMD  238.03
-2.53 (-1.05%)
BAC  51.52
-0.52 (-1.00%)
GOOG  251.34
-5.68 (-2.21%)
META  733.27
+1.10 (0.15%)
MSFT  517.66
+0.87 (0.17%)
NVDA  181.16
-1.48 (-0.81%)
ORCL  275.15
-2.03 (-0.73%)
TSLA  442.60
-4.83 (-1.08%)
FinancialContent
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap